Dealmakers seek to reset biotech clock at J.P. Morgan conference

As biotech companies and financiers focus on the J.P. Morgan Healthcare Conference — the most important industry confab for deal hookups — it is clear that the crazy days of unconstrained optimism have given way to a reality of mergers, acquisitions and sighs.
More than a quarter of the 43 Bay Area companies that presented at the conference in January 2008 have closed, been sold or merged over the past four years. What’s more, 17 of the 27 surviving publicly traded companies have seen their stock price fall, some more than 90 percent
(San Francisco Business Times subscription required.)